Picard Medical financials
$4.45−3.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $3.0M | $1.1M | $1.0M | $1.2M |
| Gross profit | $616.0K | $275.0K | $411.0K | -$130.0K |
| Gross margin | 20.9% | 23.9% | 40.7% | −11.0% |
| Operating income | -$4.6M | -$4.5M | -$3.0M | -$3.5M |
| Net income | -$5.7M | -$7.6M | -$4.3M | -$10.4M |
| Net margin | −191.6% | −662.3% | −425.3% | −878.3% |
| Diluted EPS | $-3.05 | $-5.00 | $-2.61 | $-9.50 |
| EBITDA | -$4.6M | -$4.5M | -$3.0M | -$3.4M |
| Operating cash flow | -$1.4M | -$3.8M | -$4.4M | -$6.5M |
| Free cash flow | -$1.4M | -$3.8M | -$4.4M | -$6.5M |
| Diluted shares | 1.9M | 1.5M | 1.6M | 1.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $38.0K | $121.0K | $7.5M | $2.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $657.0K | $2.2M | $5.6M | $108.0K |
| Total assets | $9.2M | $11.2M | $22.5M | $13.5M |
| Total liabilities | $7.5M | $12.7M | $18.8M | $5.6M |
| Shareholders' equity | $1.7M | -$1.4M | $3.8M | $8.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology